| Document |
Document Title |
|
WO/2008/109936A1 |
The present invention provides a compound of Formula I, pharmaceutical compositions and methods of use thereof.
|
|
WO/2008/100769A2 |
The present invention relates to processes for selective sulfation of an aromatic hydroxyl group over an aliphatic hydroxyl group where both are present in the same molecule. This invention also relates to processes for selective sulfati...
|
|
WO/2008/091540A2 |
The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obes...
|
|
WO/2007/144363A2 |
A novel process for preparing a compound of formula (I), which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof (III), without isolating any intermediates.
|
|
WO/2007/144668A2 |
The present invention relates to a process for the preparation of steroidal 17β-carboxylic thioates. More particularly the present invention relates to a convenient and efficient synthesis of steroidal 17β-carboxylic thioates, such as ...
|
|
WO/2007/144674A1 |
The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpreg
na-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestoge...
|
|
WO/2007/099548A2 |
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...
|
|
WO/2007/025780A2 |
Compounds of the formula (I), (R1 is one of a wide range of substituents; R2 = H, halogen and R3 = H, hydroxymethyl or CR2R3 = cyclopropyl ring; CR4R5 is one of formula (II), formula (III) and formula (IV) Ra and Rb are a bond between ca...
|
|
WO/2007/012228A1 |
A method for preparing S-fluoromethyl-6α, 9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-ox
oandrosta-1, 4-diene-17β-carbothioate (fluticasone propionate) was disclosed. The present method could be conduct simply and conveni...
|
|
WO2005077968B1 |
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...
|
|
WO2006043015B1 |
A process for preparing compounds of formula: (II) by esterification of the C-17 hydroxyl group of 6a, 9a-difluoro-11ß, 17a-dihydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17ß-carbot
hioic acid, the compound of formula: (I) comprises trea...
|
|
WO/2006/108572A2 |
There are provided crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I), characterised in that the particles are in the form of substantially triangular plates.
|
|
WO2006003013B1 |
The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R2 is an C1-C8 alkyl saturated or unsaturated group, an C1-C5-alkyloxy group, an aralkyl- or alkylaryl rest, an -O-CnFmHo rest, wherein n=...
|
|
WO/2006/055009A1 |
Compounds that function as lamprey attractants and methods.
|
|
WO/2006/032885A2 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2006/021776A1 |
A salt of a compound of formula (I) may be made with methanesulfonic acid. The salt and salts with other acids may be prepared by recovering from methyl tert-butyl ether (MTBE).
|
|
WO/2006/021777A1 |
A compound of formula (I) or a pharmaceutically-acceptable salt thereof, may be made by a process including a triflating step by which a ketone of formula (II) is converted into a triflate of formula (III) in the presence of a base compr...
|
|
WO/2006/005634A1 |
Crystalline polymorphic Forms A or B of 11β-[4-[5-[(4,4,5,5,5-pentafluoropentyl)suIfonyl]pentylox
y] phenyl]-estra-1,3,5(10)-triene-3,17β-diol, their preparation, use and the pharmaceutical compositions comprising Form B.
|
|
WO/2005/105823A1 |
The invention relates to compounds of formula (I) and their salts, wherein R1 is straight- or branched-chain alkyl of l-4 carbon atoms or halogen-substituted straight- or branched-chain alkyl; wherein halogen is fluorine, chlorine, bormi...
|
|
WO/2005/054271A1 |
The present invention provides an ecdysteroid derivative in which a fluorescent moiety is attached to an ecdysteroid moiety by derivatisation of a hydroxyl group on the alkyl side chain of the ecdysteroid moiety. The derivative is capabl...
|
|
WO/2005/042422A2 |
An optical fiber, and a method of making such optical fiber, wherein the optical fiber exhibits a beatlength greater than about 0.5 meters, and the fiber is spun to provide a polarization mode dispersion in the spun state of said fiber w...
|
|
WO/2005/030120A2 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO/2005/009361A2 |
This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia.
|
|
WO/2004/092193A1 |
Process for preparing ursodeoxycholic acid di-sodium 3,7-disulfate comprising: a) reacting ursodeoxycholic acid with sulfamic acid to give ursodeoxycholic acid di-ammonium 3,7-disulfate; b) treating ursodeoxycholic acid di-ammonium 3,7-d...
|
|
WO/2004/087731A1 |
A method for the conversion of steroidal 17β-carboxylic acids to c carbothioic acid and esters thereof such as fluticasone propionate.
|
|
WO/2004/074309A1 |
The invention relates to D-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates of general formula (I), wherein R3 is C1-C5 alkyl or a C1-C5 alkyloxy group and to the use thereof for producing a drug for curing tumoral diseases whi...
|
|
WO/2004/074308A1 |
The invention relates to the use of compounds of a general formula (I), wherein R2, R14 to R17 and X groups have the following significance: R2 is C1-C5-Alkyl, C1-C5-Alkoxy or a -O-CNFmHo rest, wherein n=1,2,3,4,5 or 6, m>1 and m+o=2n+1,...
|
|
WO/2004/058795A1 |
The invention provides sterol sulphate compounds according to formula (I) and compositions that are capable of promoting angiogenesis. The invention also provides methods and uses for these compounds. In said formula, R is a linear or br...
|
|
WO/2004/052912A1 |
Process for the preparation of polyhalogenated steroids, in particular of androstanic fluoro derivatives corticosteroids by means of the formation of new androstanic S-hydroxy alkyl or aralkyl-17-carbothioate intermediates.
|
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/024745A2 |
There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline complex is of space group P212121 havi...
|
|
WO/2004/012653A2 |
This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a...
|
|
WO/2004/009613A1 |
There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121...
|
|
WO/2004/000795A1 |
A process for producing easily and at a low cost vinyl perfluoroalkanesulfonate derivatives of the general formula (IV) useful as intermediates in the synthesis of drugs, natural products, and so on, characterized by reacting a carbonyl ...
|
|
WO/2004/001369A2 |
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoand
rosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treati...
|
|
WO/2003/105775A2 |
This invention relates to a powder formulation comprising a dihydrate dehydroepiandrosterone covalently bound to a sulfate, its analogue(s) or salt(s) by itself and with a pharmaceutically or veterinarily acceptable carrier, and having a...
|
|
WO/2003/086303A2 |
The invention relates to compounds of formula (I) in which n, R3, R4, R5, R6, R10, R13, R17, X, Y, and Z are defined above. The invention also relates to pharmaceutical compositions each containing an effective amount of one or more comp...
|
|
WO/2003/082896A2 |
The process for the preparation of 6&agr -fluoro steroids, comprising the reaction of the corresponding 6β-fluoro steroids, or of 6&agr /6β isomeric mixtures with an organic base having a diazo iminic group, in a suitably selected orga...
|
|
WO/2003/066655A1 |
According to one aspect of the invention, there is provided a compound of formula (I) in the form of a substantially amorphous solid.
|
|
WO/2003/066653A2 |
A process for preparing fluticasone propionate as crystalline polymorphic Form 1 which comprises reacting a compound of formula (II)or a salt thereof with a compound of formula LCH2F wherein L represents leaving group optionally in the p...
|
|
WO/2003/066657A1 |
The process for the preparation of ursodeoxycholic acid disulphate or its pharmaceutically acceptable salts comprises the operation of reacting the ursodeoxycholic acid dissolved in a solvent, selected from the group consisting of dime...
|
|
WO/2003/066654A1 |
A process for preparing a compound of formula (II) or a salt thereof is described.
|
|
WO/2003/066036A1 |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long−acting β2−adrenoreceptor agon...
|
|
WO/2003/066063A1 |
A pharmaceutical composition comprising a compound of formula (I), or a solvate thereof, in combination with a muscarinic receptor antagonist.
|
|
WO/2003/066656A1 |
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121 having u...
|
|
WO/2003/057855A2 |
A process of producing a stable composition comprising a mixture of sulfated estrogens. The mixture of sulfated estrogens may comprise sulfated alkali metal salts of &Dgr 8,9-dehydroestrone, estrone, and derivatives thereof or other estr...
|
|
WO/2003/057167A2 |
A process of producing a stable composition comprising a mixture of sulfated estrogens. The mixture of sulfated estrogens may comprise sulfated alkali metal salts of &Dgr 8,9−dehydroestrone, estrone, and derivatives thereof or other es...
|
|
WO2002009683A9 |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed.
|
|
WO/2003/042229A1 |
A compound of formula (I) wherein R1 represents O, S or NH; R2 represents a 4-7 membered non-aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl groups and/or halogen atoms; R3...
|
|
WO/2003/042230A1 |
A compound of formula (I), wherein R1 represents O, S or NH; R2 represents a 4-7 membered non-aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl groups and/or halogen atoms; R...
|
